Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1335071 | 1.00 | HPGD (0.48) | HPGDMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL57238 | 1.00 | HPGD (0.48) | HPGDMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL1068169 | 0.91 | MEN1 (0.54) | HPGDMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL1068166 | 0.91 | MEN1 (0.54) | HPGDMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL1068167 | 0.91 | MEN1 (0.54) | HPGDMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL56417 | 0.90 | HPGD (0.54) | HPGDMAPTALDH1A1RECQLEPHX1 | |
| SCHEMBL1333807 | 0.86 | NR1H2 (0.50) | HPGDMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL16935663 | 0.84 | HPGD (0.56) | HPGDMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL23207055 | 0.83 | HPGD (0.50) | HPGDMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL22680124 | 0.83 | HPGD (0.50) | HPGDMAPTMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220267260-A1 | COMPOUNDS CONTAINING A SULFONIC GROUP AS KAT INHIBITORS | Epizyme, Inc. | 2022-08-25 | — | — | US | disclosed |
| US-8933116-B2 | Gamma secretase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933116-B2 | Gamma secretase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8748614-B2 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-8748614-B2 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-8748614-B2 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-8653063-B2 | N-substituted saturated heterocyclic sulfone compounds with CB2 receptor agonistic activity | RAQUALIA PHARMA INC. (JP) | 2014-02-18 | — | — | US | disclosed |
| US-8653063-B2 | N-substituted saturated heterocyclic sulfone compounds with CB2 receptor agonistic activity | RAQUALIA PHARMA INC. (JP) | 2014-02-18 | — | — | US | disclosed |
| US-8653063-B2 | N-substituted saturated heterocyclic sulfone compounds with CB2 receptor agonistic activity | RAQUALIA PHARMA INC. (JP) | 2014-02-18 | — | — | US | disclosed |
| US-20140018342-A1 | GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-01-16 | — | — | US | disclosed |
| US-20070203122-A1 | Derivatives for modulation of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-30 | — | — | US | disclosed |
| US-20070203122-A1 | Derivatives for modulation of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-30 | — | — | US | disclosed |
| US-20070203122-A1 | Derivatives for modulation of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-30 | — | — | US | disclosed |
| WO-2007050522-A1 | DERIVATIVES FOR MODULATION OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-03 | — | — | WO | disclosed |
| WO-2006078752-A2 | INHIBITORS OF DNA METHYLTRANSFERASE | METHYLGENE, INC. (CA) | 2006-07-27 | — | — | WO | disclosed |
| EP-1278728-B1 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2004-08-25 | — | — | EP | disclosed |
| EP-1278728-A1 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-29 | — | — | EP | disclosed |
| US-6451819-B2 | PYRROLIDINE-3-YL-SULFANYL, OR SUFONYL OR SUFINYL DERIVATIVES USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | HOFFMANN-LA ROCHE INC. | 2002-09-17 | — | — | US | disclosed |
| US-20010047031-A1 | Heterocyclic compounds useful as NMDA receptor selective subtype blockers | HOFFMANN-LA ROCHE INC. | 2001-11-29 | — | — | US | disclosed |
| WO-2001081303-A1 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREAMENT OF NEURODEGENERATIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203122-A1 | Derivatives for modulation of ion channels | TRPV1, TRPA1, TRPV2 | HPGD 1667/4885MAPT 2230/4885MEN1 4785/4885 |
| US-20140018342-A1 | GAMMA SECRETASE INHIBITORS | BACE1, BACE2, PSEN1 | HPGD 1842/4885MAPT 53/4885MEN1 2642/4885 |
| US-20220267260-A1 | COMPOUNDS CONTAINING A SULFONIC GROUP AS KAT INHIBITORS | KAT5, KAT2A, KAT7 | HPGD 3496/4885MAPT 1283/4885MEN1 4099/4885 |
| US-20010047031-A1 | Heterocyclic compounds useful as NMDA receptor selective subtype blockers | GRIN1, GRM1, GRIN2B | HPGD 1965/4885MAPT 1856/4885MEN1 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.